Based on what you have written about PRS, I don't think we agree on the limitations. I am also pro free market, pro access to information, etc, etc, but also pro quality standards, not only for the genotyping (which is peanuts) but for the modeling and assessment.
The conclusion of that paper is that due to their low absolute risk, screening healthy younger participants is not advised
-
-
Well - I think the issue is that you are mixing issues of public policy with personal choice. At least that is my view of the situation.
-
In what sense? Personal choice is wonderful language, but monitoring your diabetes status over a lifetime requires tens of thousands in lab tests, not to mention the cost of the test itself. Where's the value?
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.